Developer of healthcare software intended to provide reliable, timely, and affordable care for patients with their homes
Developer of healthcare software intended to provide reliable, timely, and affordable care for patients with their homes.
Clinics/Outpatient Services📍 New York, NYFounded 2018
Current Valuation
$735.18M
as of 2025-Q2
PRIVATE
QL Price
$546.83M
-26% vs last round
QuantLogix's current estimate for Verse Medical, published 2026-09-27 — below the last disclosed round of $735.18M (2025-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$735.18M
2025-Q2
weight 0.42
Secondary market print
$408.76M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Verse Medical since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Verse Medical, 2026-09-27 (05cf685b16310113).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Verse Medical going public?
No. Verse Medical is private and has not filed to go public. There is no S-1 on file.
What is Verse Medical's valuation in 2026?
Verse Medical is valued at $735.18M as of 2025-Q2, set by its Series C ($53M, Jun 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Verse Medical filed an S-1?
No public S-1 is on file for Verse Medical.
How much has Verse Medical raised?
Verse Medical has raised $109.43M in total, most recently a Series C of $53M in Jun 2025.
Is Verse Medical publicly traded — can you buy Verse Medical stock?
No. Verse Medical is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Verse Medical on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
New York, NY
Employees
136
Total Raised
$109.43M
Last Round
Series C — $53M (Jun 2025)
IPO Status
private
Fundraising Status
Series C · $53M · 1y 3mo ago
privateTotal raised $109.43M
Secondary Market
Implied price / share
$18
Last round price / share
$32.37
vs last round
-44.4%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$53M
Jun 2025
—
$735.18M
Talent Signal
Hiring trend
▲ Hiring uptrend
+23% vs 2026-08
Open roles
27
via ashby
Product-build share
33%
engineering, research, product, design
Trajectory
expanding
balanced build + GTM — 33% builders vs 67% go-to-market/G&A — scaling both sides.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Medical BillerSoftware Engineer, Full Stack - Emerging TalentSenior Software Engineer, Full StackStaff Software Engineer, Full StackSoftware Engineer, Full StackSenior Data Engineer
Counted from Verse Medical's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareSaaSLife Science
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.